The New England journal of medicine 2021 Mar 25
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Related Questions
New comment by Medical Oncologist at University of North Carolina at Chapel Hill ( April 24, 2022)
At N2 disease, I would worry about using genomic testing to predict the biology of the tumor and would not make adjuvant therapy decisions based on it, especially when data ...